Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

News
2024
2023
Archive
Search news articles

October 27, 2021

Pear Therapeutics and Thimble Point Aquisition Corp. Announce Effectiveness of S-4 Registration Statement and Set November 23, 2021 for Thimble Point Special Stockholder Meeting to Vote on Proposed Business Combination
October 21, 2021

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
October 21, 2021

Artiva Biotherapeutics to Present Preclinical Data for AB-201, a HER2-Targeting CAR-NK Cell Therapy, at SITC 36th Annual Meeting
October 21, 2021

Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting
October 20, 2021

Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting
October 20, 2021

Novome Biotechnologies Appoints Bill McLeod as Chief Financial Officer
October 19, 2021

Radionetics Oncology Emerges From Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology
October 18, 2021

IDEAYA Biosciences Appoints Michael White, Ph.D., as Chief Scientific Officer
October 18, 2021

Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)
October 12, 2021

Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU